Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Peña · SciRah

Researcher profile · Semantic Scholar

C. Peña

Share profile

C. Peña — researcher profile on SciRah

h-index: 26
Works: 91
Citations: 5,569

Most-cited papers

Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase 3 trial
M. Brose, C. Nutting, B. Jarzab, R. Elisei +13 more
2014The Lancet1,339 citations Open access
Semantic Scholar
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
B. Escudier, T. Eisen, W. Stadler, C. Szczylik +15 more
2009Journal of Clinical Oncology1,105 citations Open access
Semantic Scholar
Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
J. Llovet, C. Peña, C. Lathia, M. Shan +2 more
2012Clinical Cancer Research552 citations Open access
Semantic Scholar
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
M. Dreyling, A. Santoro, L. Mollica, S. Leppä +23 more
2017Journal of Clinical Oncology351 citations
Semantic Scholar
Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial
R. Pinyol, R. Montal, L. Bassaganyas, D. Sia +26 more
2018Gut292 citations Open access
Semantic Scholar
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
M. Dreyling, F. Morschhauser, K. Bouabdallah, D. Bron +16 more
2017Annals of Oncology248 citations Open access
Semantic Scholar
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
A. Patnaik, L. Appleman, A. Tolcher, K. Papadopoulos +17 more
2016Annals of Oncology217 citations Open access
Semantic Scholar
Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
C. Peña, C. Lathia, M. Shan, B. Escudier +1 more
2010Clinical Cancer Research169 citations
Semantic Scholar
Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis
R. Bukowski, T. Eisen, C. Szczylik, W. Stadler +5 more
2007143 citations
Semantic Scholar
Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer
G. Bianchi, S. Loibl, C. Zamagni, S. Salvagni +7 more
2009Anti-Cancer Drugs111 citations
Semantic Scholar
Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens.
L. Paz-Ares, V. Hirsh, Li Zhang, F. de Marinis +13 more
2015Journal of Thoracic Oncology100 citations Open access
Semantic Scholar
AKT1E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection
M. Rudolph, T. Anzeneder, A. Schulz, G. Beckmann +7 more
2016BMC Cancer90 citations Open access
Semantic Scholar
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
D. M. Vega, Katherine K. Nishimura, Névine Zariffa, Jeffrey C. Thompson +31 more
2022JCO Precision Oncology69 citations Open access
Semantic Scholar
Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma
G. Lenz, E. Hawkes, G. Verhoef, C. Haioun +15 more
2020Leukemia59 citations Open access
Semantic Scholar
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
A. Wick, O. Bähr, M. Schuler, K. Rohrberg +27 more
2021Clinical Cancer Research57 citations
Semantic Scholar
Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
R. Ramanathan, D. V. Von Hoff, F. Eskens, G. Blumenschein +7 more
2020Targeted oncology45 citations Open access
Semantic Scholar
Small cell lung cancer in never-smokers
M. Torres-Durán, A. Ruano-Raviña, K. Kelsey, I. Parente-Lamelas +13 more
2015European Respiratory Journal45 citations Open access
Semantic Scholar
Breast cancer, early stage
Tony S. K. Mok, L. Paz-Ares, Y.-L. Wu, S. Novello +496 more
201245 citations Open access
Semantic Scholar
Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
R. Kim, S. Alberts, C. Peña, I. Genvresse +4 more
2018British Journal of Cancer37 citations Open access
Semantic Scholar
Recovery of microarray-quality RNA from frozen EDTA blood samples.
J. Beekman, J. Reischl, D. Henderson, David Bauer +4 more
2009Journal of pharmacological and toxicological methods36 citations
Semantic Scholar
On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
F. Morschhauser, J. Machiels, G. Salles, S. Rottey +17 more
2019Molecular Cancer Therapeutics34 citations Open access
Semantic Scholar
Preclinical Antitumor Efficacy of BAY 1129980—a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody–Drug Conjugate for the Treatment of Non–Small Cell Lung Cancer
J. Willuda, Lars Linden, H. Lerchen, C. Kopitz +19 more
2017Molecular Cancer Therapeutics34 citations Open access
Semantic Scholar
Alpha-1 Antitrypsin Deficiency and Lung Cancer Risk: A Case–Control Study in Never-Smokers
M. Torres-Durán, A. Ruano-Raviña, I. Parente-Lamelas, J. Abal-Arca +12 more
2015Journal of Thoracic Oncology32 citations Open access
Semantic Scholar
Genetic variants of VEGFA and FLT4 are determinants of survival in renal cell carcinoma patients treated with sorafenib
D. Crona, A. Skol, Veli-Matti Leppänen, Dylan M Glubb +7 more
2018Cancer Research29 citations Open access
Semantic Scholar
Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial
A. Zhu, Yoon-Koo Kang, O. Rosmorduc, T. R. Jeffry Evans +7 more
2016Clinical Cancer Research29 citations Open access
Semantic Scholar
MISSION Trial - A phase III, multi-center, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly non-squamous NSCLC after 2 or 3 previous treatment regimens.
L. Paz-Ares, V. Hirsh, Li Zhang, F. de Marinis +13 more
2015Journal of Thoracic Oncology29 citations
Semantic Scholar
Exposure to Residential Radon and Lung Cancer in Never-smokers: The Preliminary Results of the LCRINS Study
A. Ruano-Raviña, Luciana Prini-Guadalupe, J. Barros-Dios, J. Abal-Arca +9 more
201222 citations
Semantic Scholar
HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma
Shi-Ming Lin, Sheng-Nan Lu, Ping-Tsung Chen, L. Jeng +10 more
2016Hepatology International18 citations Open access
Semantic Scholar
Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial
M. Brose, Martin Schlumbeger, M. Jeffers, C. Kappeler +2 more
2019Clinical Cancer Research16 citations Open access
Semantic Scholar
A phase 1b trial of PI3K inhibitor copanlisib (BAY 80-6946) combined with the allosteric-MEK inhibitor refametinib (BAY 86-9766) in patients with advanced cancer.
R. Ramanathan, D. V. Von Hoff, F. Eskens, G. Blumenschein +6 more
201416 citations
Semantic Scholar
Non-small cell lung cancer, locally advanced
S. Ou, D. Camidge, J. Engelman, Jeffrey W. Clark +222 more
201216 citations Open access
Semantic Scholar
SORAFENIB IN ADVANCED RENAL CELL CARCINOMA (RCC): SURVIVAL AND BIOMARKER RESULTS FROM A PHASE III TRIAL
R. Bukowski, D. Heng, T. Eisen, C. Szczylik +7 more
200816 citations
Semantic Scholar
Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial
J. Capdevila, I. Matos, F. Mancuso, C. Iglesias +12 more
2019Molecular Cancer Therapeutics14 citations
Semantic Scholar
Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
G. Lenz, E. Hawkes, G. Verhoef, C. Haioun +14 more
201714 citations
Semantic Scholar
Sorafenib (S) and dacarbazine (D) combination in patients (pts) with advanced malignant solid tumors: Phase I study with tumor biopsy genomic analysis and dynamic contrast enhanced ultrasonography (DCE-US)
J. Soria, V. Lazar, N. Lassau, C. Peña +6 more
200712 citations
Semantic Scholar
Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC
G. Blumenschein, M. Reck, F. Fossella, D. Stewart +2 more
2011Cancer Biomarkers11 citations Open access
Semantic Scholar
1057 PLASMA BIOMARKERS AS PREDICTORS OF OUTCOME IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: RESULTS FROM THE RANDOMIZED PHASE III SHARP TRIAL
J. Llovet, C. Peña, M. Shan, C. Lathia +1 more
200911 citations
Semantic Scholar
PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors
J. Quintanilha, A. Racioppi, J. Wang, S. Denning +5 more
2019Annals of Oncology9 citations Open access
Semantic Scholar
Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial.
L. Bastholt, M. Brose, B. Jarzab, M. Schlumberger +15 more
20148 citations
Semantic Scholar
CLINICAL OUTCOMES AND MOLECULAR CHARACTERIZATION FROM a PHASE II STUDY OF COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
Georg Lenz, E. Hawkes, G. Verhoef, C. Haioun +15 more
20177 citations Open access
Semantic Scholar
COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B‐CELL LYMPHOMA (CHRONOS‐1)
M. Dreyling, A. Santoro, L. Mollica, S. Leppä +22 more
20177 citations Open access
Semantic Scholar
Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples
V. Lazar, N. Lassau, G. Meurice, Y. Loriot +9 more
2014Investigational new drugs7 citations
Semantic Scholar
KDR genetic predictor of toxicities induced by sorafenib and regorafenib
J. Quintanilha, Susan Geyer, A. Etheridge, A. Racioppi +10 more
2022The Pharmacogenomics Journal6 citations Open access
Semantic Scholar
Exposure–Response Modeling and Simulation of Progression‐Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer
J. Grevel, Garrit Jentsch, Rupert Austin, N. H. Prins +8 more
2019Clinical and Translational Science5 citations Open access
Semantic Scholar
Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
F. Marmé, C. Gomez-Roca, K. Graudenz, Fu-Nan Huang +4 more
2018Cancer Chemotherapy and Pharmacology5 citations
Semantic Scholar
No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects
Fu-Nan Huang, A. Ajavon, Erya Huang, J. Lettieri +3 more
2017Thyroid5 citations Open access
Semantic Scholar
Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial
R. Pinyol, R. Montal, T. Takayama, G. Chau +26 more
20175 citations
Semantic Scholar
Association between tumor BRAF and RAS mutation status and clinical outcomes in patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) randomized to sorafenib or placebo: sub-analysis of the phase III DECISION trial
R. Paschke, M. Brose, C. Nutting, Y. Shong +7 more
20145 citations
Semantic Scholar
Chapter 4. A Systems Biology Approach to Target Identification and Validation for Human Chronic Disease Drug Discovery
B. G. Gould Rothberg, C. Peña, J. Rothberg
20085 citations
Semantic Scholar
Biomarkers of prognosis in patients with differentiated thyroid cancer: Results from the DECISION trial.
C. Peña, S. Wilhelm, G. Meinhardt, M. Schlumberger +1 more
20164 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

C. Lathia×8
Invite
C. Lathia — researcher profile on SciRah
G. Meinhardt×7
Invite
G. Meinhardt — researcher profile on SciRah
M. Brose×6
Invite
M. Brose — researcher profile on SciRah
M. Schlumberger×6
Invite
M. Schlumberger — researcher profile on SciRah

×6

Invite

F. Hiemeyer — researcher profile on SciRah

Invite

B. Childs — researcher profile on SciRah

Invite

M. Jeffers — researcher profile on SciRah

I. Genvresse×5

Invite

I. Genvresse — researcher profile on SciRah

Invite

B. Escudier — researcher profile on SciRah

Invite

R. Bukowski — researcher profile on SciRah

Invite

J. Llovet — researcher profile on SciRah

Invite

M. Shan — researcher profile on SciRah